CD298 (ATP1B3) is a 42 kDa type II transmembrane protein serving as the β3 subunit of Na+/K+ ATPase. It facilitates ion transport across cell membranes and exhibits broad expression in leukocytes and other tissues .
| Property | CD298 Antibody Details |
|---|---|
| Target Antigen | β3 subunit of Na+/K+ ATPase (ATP1B3) |
| Clone | LNH-94 (mouse IgG1κ) |
| Applications | Flow cytometry (FC) |
| Epitope Specificity | Conformational epitope on extracellular domain |
| Regulatory Status | Research Use Only (RUO) |
Source: BioLegend product specifications
While CD298 itself is not an immunoglobulin, rheumatoid factors (RFs) targeting IgG-Fc regions share mechanistic parallels with ion channel-targeting antibodies:
RFs bind cryptic epitopes in the CH2/CH3 groove of IgG-Fc, exposed during immune complex formation .
CD298 antibodies interact with conformational epitopes critical for Na+/K+ ATPase function .
| Parameter | Rheumatoid Factors | CD298 Antibodies |
|---|---|---|
| Target Region | IgG-Fc (CH2/CH3 interface) | Na+/K+ ATPase β3 subunit |
| Pathogenic Role | Autoimmune disorders (e.g., RA) | Not directly linked to autoimmunity |
| Detection Method | ELISA, nephelometry | Flow cytometry |
CD298 antibodies (e.g., clone LNH-94) are validated for:
Leukocyte profiling: Detecting ATP1B3 expression across immune cell subsets .
Ion transport studies: Mapping Na+/K+ ATPase distribution in epithelial and neural tissues .
Dual ELISA approaches (as used for IgM-RF quantification ) could enhance CD298 assay specificity.
Epitope mapping techniques (e.g., engineered IgG mutants ) may refine CD298 antibody validation.
Nomenclature clarity: "RF298" may reflect a typographical error or proprietary commercial designation not yet indexed in peer-reviewed literature.
Functional studies: Further research is needed to explore autoimmune cross-reactivity between RFs and ion channel targets like CD298.